scholarly journals The Type 2 Asthma Mediator IL-13 Inhibits SARS-CoV-2 Infection of Bronchial Epithelium

2022 ◽  
Author(s):  
Luke R Bonser ◽  
Walter L. Eckalbar ◽  
Lauren Rodriguez ◽  
Jiangshan Shen ◽  
Kyung Duk Koh ◽  
...  
Keyword(s):  
Bronchial Epithelium

scholarly journals The type 2 asthma mediator IL-13 inhibits SARS-CoV-2 infection of bronchial epithelium

2021 ◽  
Author(s):  
Luke R. Bonser ◽  
Walter L. Eckalbar ◽  
Lauren Rodriguez ◽  
Jiangshan Shen ◽  
Kyung Duk Koh ◽  
...  
Keyword(s):  
Gene Expression ◽  
Airway Epithelium ◽  
Limit Of Detection ◽  
Bronchial Epithelium ◽  
Type I Interferons ◽  
Chronic Obstructive ◽  
Type I ◽  
Obstructive Pulmonary Disease ◽  
Genes Encoding

AbstractRationaleAsthma is associated with chronic changes in the airway epithelium, a key target of SARS-CoV-2. Many epithelial changes are driven by the type 2 cytokine IL-13, but the effects of IL-13 on SARS-CoV-2 infection are unknown.ObjectivesWe sought to discover how IL-13 and other cytokines affect expression of genes encoding SARS-CoV-2-associated host proteins in human bronchial epithelial cells (HBECs) and determine whether IL-13 stimulation alters susceptibility to SARS-CoV-2 infection.MethodsWe used bulk and single cell RNA-seq to identify cytokine-induced changes in SARS-CoV-2-associated gene expression in HBECs. We related these to gene expression changes in airway epithelium from individuals with mild-moderate asthma and chronic obstructive pulmonary disease (COPD). We analyzed effects of IL-13 on SARS-CoV-2 infection of HBECs.Measurements and Main ResultsTranscripts encoding 332 of 342 (97%) SARS-CoV-2-associated proteins were detected in HBECs (≥1 RPM in 50% samples). 41 (12%) of these mRNAs were regulated by IL-13 (>1.5-fold change, FDR < 0.05). Many IL-13-regulated SARS-CoV-2-associated genes were also altered in type 2 high asthma and COPD. IL-13 pretreatment reduced viral RNA recovered from SARS-CoV-2 infected cells and decreased dsRNA, a marker of viral replication, to below the limit of detection in our assay. Mucus also inhibited viral infection.ConclusionsIL-13 markedly reduces susceptibility of HBECs to SARS-CoV-2 infection through mechanisms that likely differ from those activated by type I interferons. Our findings may help explain reports of relatively low prevalence of asthma in patients diagnosed with COVID-19 and could lead to new strategies for reducing SARS-CoV-2 infection.

Diabète de type 2 : les médicaments hypoglycémiants et leurs risques cardiovasculaires

2017 ◽  
Vol 201 (7-9) ◽  
pp. 1209-1225
Author(s):  
Bernard Bauduceau ◽  
Lyse Bordier
Keyword(s):  
Diabète De Type 2

Does short-term administration of glucagon-like peptide type 2 affect bone mass and markers of bone remodeling in short bowel patients?

2001 ◽  
Vol 120 (5) ◽  
pp. A314-A314
Author(s):  
K HADERSLEV ◽  
P JEPPESEN ◽  
B HARTMANN ◽  
J THULESEN ◽  
J GRAFF ◽  
...  
Keyword(s):  
Bone Mass ◽  
Bone Remodeling ◽  
Short Term ◽  
Short Bowel ◽  
Term Administration ◽  
Glucagon Like Peptide
Sign in / Sign up

Export Citation Format

Share Document